Download PDFPDF

Successful treatment with interferon alfa in infiltrating angiolipoma: a case presenting with Kasabach-Merritt syndrome
Compose Response

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g.
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests


  • A rapid response is a moderated but not peer reviewed online response to a published article in a BMJ journal; it will not receive a DOI and will not be indexed unless it is also republished as a Letter, Correspondence or as other content. Find out more about rapid responses.
  • We intend to post all responses which are approved by the Editor, within 14 days (BMJ Journals) or 24 hours (The BMJ), however timeframes cannot be guaranteed. Responses must comply with our requirements and should contribute substantially to the topic, but it is at our absolute discretion whether we publish a response, and we reserve the right to edit or remove responses before and after publication and also republish some or all in other BMJ publications, including third party local editions in other countries and languages
  • Our requirements are stated in our rapid response terms and conditions and must be read. These include ensuring that: i) you do not include any illustrative content including tables and graphs, ii) you do not include any information that includes specifics about any patients,iii) you do not include any original data, unless it has already been published in a peer reviewed journal and you have included a reference, iv) your response is lawful, not defamatory, original and accurate, v) you declare any competing interests, vi) you understand that your name and other personal details set out in our rapid response terms and conditions will be published with any responses we publish and vii) you understand that once a response is published, we may continue to publish your response and/or edit or remove it in the future.
  • By submitting this rapid response you are agreeing to our terms and conditions for rapid responses and understand that your personal data will be processed in accordance with those terms and our privacy notice.
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

Other responses

Jump to comment:

  • Published on:
    Author's reply
    • Suna Emir, Pediatric Oncologist
    • Other Contributors:
      • Canan Akyüz.

    Dear Editor

    We thank Dr Biban for his comments on our article.[1] We share his concerns that our case has some interesting and unique points. As he/she stated that our case was the first reported case of a Kasabach-Merrit syndrome (KSM) associated with a lipomatous tumor. Her severe findings due to KSM and as well as her progressively enlarging mass on the shoulder were dramatically responded to interferon therapy.[...

    Show More
    Conflict of Interest:
    None declared.
  • Published on:
    Kasabach-Merritt syndrome and interferon alpha: still a controversial issue.

    Dear Editor

    We read with interest the paper by Akyuz and colleagues,[1] which described a 2 year old patient with a Kasabach-Merritt syndrome (KMS) secondary to an infiltrating angiolipoma, who was successfully treated with interferon alpha 2a (IFN-alpha).

    Although the case presents some points of interest, such as the previously unreported association of a KMS with a lipomatous tumor and the potential effec...

    Show More
    Conflict of Interest:
    None declared.